Evidence map›Paper›PMID 30145635›Full record

ArticleClinical rheumatology2019

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Evangelia Zampeli, Aliki Venetsanopoulou, Ourania D Argyropoulou, Clio P Mavragani, Maria G Tektonidou, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas, Fotini N Skopouli, Haralampos M Moutsopoulos

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Antisynthetase syndrome: A distinct disease spectrum.Journal of scleroderma and related disorders · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Evangelia ZampeliInstitute for Systemic Autoimmune and Neurological Diseases, Athens, Greece. zampelieva@gmail.com.ORCID http://orcid.org/0000-0002-3668-4454
Aliki VenetsanopoulouDepartment of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ourania D ArgyropoulouDepartment of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Clio P MavraganiDepartment of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maria G TektonidouFirst Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Panayiotis G VlachoyiannopoulosDepartment of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Athanasios G TzioufasDepartment of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Fotini N SkopouliDepartment of Internal Medicine and Clinical Immunology, Euroclinic Hospital, Athens, Greece.
Haralampos M MoutsopoulosInstitute for Systemic Autoimmune and Neurological Diseases, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myositis-specific (MSAs) or-associated autoantibodies (MAAs) have been linked to particular clinical phenotypes of idiopathic inflammatory myopathies (IIM) and appear to aid diagnosis. The objective of this study was to analyze the prevalence of MSAs and MAAs and their possible clinical associations in Greek IIM patients. This study comprised 95 IIM patients classified based on the 2017 EULAR/ACR classification criteria. All patients had MSAs and MAAs measured in their sera by line immunoblot assay. Dermatomyositis was the most prevalent IIM clinical subtype. MSAs were found in 44% of the patients, whereas MAAs in 23%. The most frequently detected MSA was anti-Jo-1 (22%), while the most frequently detected MAA was anti-Ro-52 (30%). The distributions of MSAs/MAAs did not differ between the five IIM subgroups, except for anti-Mi-2 which was only detected in dermatomyositis patients. Patients with at least one MSA and/or MAA positivity showed more frequently IIM characteristic skin rashes, while those presenting solely MAA positivity had more often puffy hands and Raynaud's phenomenon. Anti-Jo1-positive patients presented more frequently lung disease, while anti-Ro52 positivity related to mechanic's hands. Anti-Ro-52 and anti-Jo-1 strongly associated with one another. Prevalence of IIM subtypes and of MSAs/MAAs in our patients is in line with published reports in populations of similar geographic distribution. While MSA and/or MAA positivity did associate with particular clinical manifestations, it did not predict in our cohort specific IIM subgroup as defined by the latest EULAR/ACR classification criteria. Future studies are warranted to conclusively decide if these autoantibodies, measured with a standardized method, should or not be incorporated in every day clinical practice to aid IIM diagnosis.

Indexed as

AdolescentAdultAgedAutoantibodiesAutoantigensBiomarkersCohort StudiesFemaleGreeceHumansMaleMiddle AgedMyositisPhenotypeYoung AdultAutoantibodiesAutoantigensBiomarkersDermatomyositisIdiopathic inflammatory myopathiesMyositis-associated autoantibodiesMyositis-specific autoantibodiesPolymyositis

Identifiers

PMID30145635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.